Corcept Therapeutics reported second-quarter 2026 revenue up 32% to $256.1 million and raised its 2026 revenue guidance to $1.1–$1.2 billion.
https://finviz.com/stock?t=CORT&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.